Tempus and Blood Cancer United Collaborate to Build Extensive Pediatric AML Data Registry

Tempus and Blood Cancer United® have announced a collaboration to create one of the largest real-world data registries for pediatric acute myeloid leukemia (AML). The initiative aims to collect and analyze comprehensive clinical and molecular data from pediatric AML patients, with the goal of advancing research and improving treatment outcomes for this rare form of blood cancer.

The registry will aggregate anonymized patient data, including genetic information, treatment histories, and clinical outcomes. By compiling this extensive dataset, researchers hope to gain deeper insights into the disease’s progression and response to various therapies. Pediatric AML is a rare but aggressive cancer that affects children, making it challenging to study due to limited available data. This partnership seeks to address that gap by creating a robust resource for clinicians and scientists working in the field.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI